Orchard Therapeutics Statistics Share Statistics Orchard Therapeutics has 22.76M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 22.76M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 117.51M Failed to Deliver (FTD) Shares 2,780 FTD / Avg. Volume 2.64%
Short Selling Information The latest short interest is 31.47K, so 0.14% of the outstanding
shares have been sold short.
Short Interest 31.47K Short % of Shares Out 0.14% Short % of Float 0.15% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -6.01 and the forward
PE ratio is null.
Orchard Therapeutics's PEG ratio is
0.08.
PE Ratio -6.01 Forward PE n/a PS Ratio 6.78 Forward PS n/a PB Ratio 0.48 P/FCF Ratio -0.57 PEG Ratio 0.08
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Orchard Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.78,
with a Debt / Equity ratio of 0.59.
Current Ratio 2.78 Quick Ratio 2.72 Debt / Equity 0.59 Debt / EBITDA -7.19 Debt / FCF -0.7 Interest Coverage -33.86
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $42.08K Profits Per Employee $-47.49K Employee Count 166 Asset Turnover 0.03 Inventory Turnover 0.72
Taxes Income Tax -1.13M Effective Tax Rate 12.53%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 0.55, so Orchard Therapeutics's
price volatility has been higher than the market average.
Beta 0.55 52-Week Price Change n/a 50-Day Moving Average 16.43 200-Day Moving Average 9.87 Relative Strength Index (RSI) 85.36 Average Volume (20 Days) 105,224
Income Statement In the last 12 months, Orchard Therapeutics had revenue of 6.99M
and earned -7.88M
in profits. Earnings per share was -0.61.
Revenue 6.99M Gross Profit 4.55M Operating Income -31.59M Net Income -7.88M EBITDA -8.08M EBIT -150.9M Earnings Per Share (EPS) -0.61
Full Income Statement Balance Sheet The company has 68.42M in cash and 58.09M in
debt, giving a net cash position of 10.33M.
Cash & Cash Equivalents 68.42M Total Debt 58.09M Net Cash 10.33M Retained Earnings -900.88M Total Assets 202.27M Working Capital 104.55M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -75.99M
and capital expenditures -6.51M, giving a free cash flow of -82.5M.
Operating Cash Flow -75.99M Capital Expenditures -6.51M Free Cash Flow -82.5M FCF Per Share -6.45
Full Cash Flow Statement Margins Gross margin is 65.17%, with operating and profit margins of -452.22% and -112.84%.
Gross Margin 65.17% Operating Margin -452.22% Pretax Margin -129% Profit Margin -112.84% EBITDA Margin -115.65% EBIT Margin -452.22% FCF Margin -1180.95%
Dividends & Yields ORTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for ORTX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Mar 10, 2023. It was a
backward
split with a ratio of 1:10.
Last Split Date Mar 10, 2023 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -3.08 Piotroski F-Score 5
